These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 25042563)

  • 21. Targeting the Hippo pathway: Clinical implications and therapeutics.
    Ye S; Eisinger-Mathason TS
    Pharmacol Res; 2016 Jan; 103():270-8. PubMed ID: 26678601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
    Chen M; Wang M; Xu S; Guo X; Jiang J
    Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis.
    Patel SH; Camargo FD; Yimlamai D
    Gastroenterology; 2017 Feb; 152(3):533-545. PubMed ID: 28003097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
    Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
    Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma.
    Wong KF; Liu AM; Hong W; Xu Z; Luk JM
    Oncotarget; 2016 Nov; 7(47):77683-77695. PubMed ID: 27765911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of the Hippo Pathway in Fibrosis and Cancer.
    Kim CL; Choi SH; Mo JS
    Cells; 2019 May; 8(5):. PubMed ID: 31100975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 28. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
    Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
    Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. YAP and TAZ Take Center Stage in Cancer.
    Zhang K; Qi HX; Hu ZM; Chang YN; Shi ZM; Han XH; Han YW; Zhang RX; Zhang Z; Chen T; Hong W
    Biochemistry; 2015 Nov; 54(43):6555-66. PubMed ID: 26465056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the transcriptional coactivators YAP/TAZ in liver cancer.
    Zhang S; Zhou D
    Curr Opin Cell Biol; 2019 Dec; 61():64-71. PubMed ID: 31387016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Arsenic-induced cutaneous hyperplastic lesions are associated with the dysregulation of Yap, a Hippo signaling-related protein.
    Li C; Srivastava RK; Elmets CA; Afaq F; Athar M
    Biochem Biophys Res Commun; 2013 Sep; 438(4):607-12. PubMed ID: 23942117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell.
    Plouffe SW; Lin KC; Moore JL; Tan FE; Ma S; Ye Z; Qiu Y; Ren B; Guan KL
    J Biol Chem; 2018 Jul; 293(28):11230-11240. PubMed ID: 29802201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crosstalk between Hippo and TGFβ: Subcellular Localization of YAP/TAZ/Smad Complexes.
    Grannas K; Arngården L; Lönn P; Mazurkiewicz M; Blokzijl A; Zieba A; Söderberg O
    J Mol Biol; 2015 Oct; 427(21):3407-15. PubMed ID: 25937570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
    Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
    Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma.
    Nallet-Staub F; Marsaud V; Li L; Gilbert C; Dodier S; Bataille V; Sudol M; Herlyn M; Mauviel A
    J Invest Dermatol; 2014 Jan; 134(1):123-132. PubMed ID: 23897276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine.
    Nagashima S; Bao Y; Hata Y
    Curr Drug Targets; 2017; 18(4):447-454. PubMed ID: 26758663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer.
    Vahid S; Thaper D; Gibson KF; Bishop JL; Zoubeidi A
    Sci Rep; 2016 Aug; 6():31842. PubMed ID: 27555231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The hippo signaling pathway in development and cancer.
    Pan D
    Dev Cell; 2010 Oct; 19(4):491-505. PubMed ID: 20951342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palmitic acid dysregulates the Hippo-YAP pathway and inhibits angiogenesis by inducing mitochondrial damage and activating the cytosolic DNA sensor cGAS-STING-IRF3 signaling mechanism.
    Yuan L; Mao Y; Luo W; Wu W; Xu H; Wang XL; Shen YH
    J Biol Chem; 2017 Sep; 292(36):15002-15015. PubMed ID: 28698384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth.
    Low BC; Pan CQ; Shivashankar GV; Bershadsky A; Sudol M; Sheetz M
    FEBS Lett; 2014 Aug; 588(16):2663-70. PubMed ID: 24747426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.